Voclosporin is a calcineurin inhibitor. By inhibiting calcineurin, it blocks IL-2 expression and T-cell mediated immune responses, which stabilises the podocyte in the kidney. It is under phase 3 clinical development in the EU for Lupus nephritis as an adjunct to use with mycophenolate.